These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 25295493)

  • 21. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of the Cre8 Stent in Patients With Diabetes Mellitus.
    Carrié D
    Interv Cardiol; 2016 May; 11(1):47-50. PubMed ID: 29588705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical impact of second-generation everolimus-eluting stent compared with first-generation drug-eluting stents in diabetes mellitus patients: insights from a nationwide coronary intervention register.
    Kedhi E; Gomes ME; Lagerqvist B; Smith JG; Omerovic E; James S; Harnek J; Olivecrona GK
    JACC Cardiovasc Interv; 2012 Nov; 5(11):1141-9. PubMed ID: 23174638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Three-year follow-up after treatment of bare-metal stent restenosis with first-generation or second-generation drug-eluting stents.
    Almalla M; Schröder JW; Pross V; Marx N; Hoffmann R
    Coron Artery Dis; 2013 Mar; 24(2):165-70. PubMed ID: 23242011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial.
    von Birgelen C; Sen H; Lam MK; Danse PW; Jessurun GA; Hautvast RW; van Houwelingen GK; Schramm AR; Gin RM; Louwerenburg JW; de Man FH; Stoel MG; Löwik MM; Linssen GC; Saïd SA; Nienhuis MB; Verhorst PM; Basalus MW; Doggen CJ; Tandjung K
    Lancet; 2014 Feb; 383(9915):413-23. PubMed ID: 24183564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study.
    Li Y; Han Y; Zhang L; Jing Q; Wang X; Yan G; Ma Y; Wang G; Wang S; Chen X; Yang L; Zhu G; Liu H; Jiang T
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):1127-33. PubMed ID: 22945767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
    Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
    JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and nondiabetic patients: two-year subgroup analysis of the ZEST randomized trial.
    Jang SJ; Park DW; Kim WJ; Kim YH; Yun SC; Kang SJ; Lee SW; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):1106-14. PubMed ID: 22899589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: rationale and design of the BIOSCIENCE trial.
    Pilgrim T; Roffi M; Tüller D; Muller O; Vuilliomenet A; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Heg D; Jüni P; Windecker S
    Am Heart J; 2014 Sep; 168(3):256-61. PubMed ID: 25173535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of 3 biodegradable polymer and durable polymer-based drug-eluting stents in all-comers (BIO-RESORT): rationale and study design of the randomized TWENTE III multicenter trial.
    Lam MK; Sen H; Tandjung K; van Houwelingen KG; de Vries AG; Danse PW; Schotborgh CE; Scholte M; Löwik MM; Linssen GC; Ijzerman MJ; van der Palen J; Doggen CJ; von Birgelen C
    Am Heart J; 2014 Apr; 167(4):445-51. PubMed ID: 24655691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Everolimus-eluting versus sirolimus-eluting coronary stents in patients with and without diabetes mellitus.
    Kang SH; Park KH; Ahn HS; Park KW; Hong YJ; Koo BK; Jeong MH; Kim HS
    EuroIntervention; 2014 May; 10(1):74-82. PubMed ID: 24345385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel drug-eluting stents for coronary revascularization.
    Gogas BD; McDaniel M; Samady H; King SB
    Trends Cardiovasc Med; 2014 Oct; 24(7):305-13. PubMed ID: 25240980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus: 4-year clinical outcomes of DES-DIABETES (drug-eluting stent in patients with DIABETES mellitus) trial.
    Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Kang SJ; Rhee KS; Chae JK; Ko JK; Park JH; Lee JH; Choi SW; Jeong JO; Seong IW; Cho YH; Lee NH; Kim JH; Chun KJ; Kim HS; Park SJ
    JACC Cardiovasc Interv; 2011 Mar; 4(3):310-6. PubMed ID: 21435609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial.
    Garg S; Serruys PW; Silber S; Wykrzykowska J; van Geuns RJ; Richardt G; Buszman PE; Kelbæk H; van Boven AJ; Hofma SH; Linke A; Klauss V; Wijns W; Macaya C; Garot P; DiMario C; Manoharan G; Kornowski R; Ischinger T; Bartorelli A; Van Remortel E; Ronden J; Windecker S
    JACC Cardiovasc Interv; 2011 Apr; 4(4):432-41. PubMed ID: 21511223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents.
    Byrne RA; Mehilli J; Iijima R; Schulz S; Pache J; Seyfarth M; Schömig A; Kastrati A
    Eur Heart J; 2009 Apr; 30(8):923-31. PubMed ID: 19240066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug-eluting stent outcomes in diabetes.
    Bernelli C; Chan J; Chieffo A
    Expert Rev Cardiovasc Ther; 2014 Jan; 12(1):95-109. PubMed ID: 24345095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of outcomes after percutaneous coronary intervention for chronic total occlusion using everolimus- versus sirolimus- versus paclitaxel-eluting stents (from the Korean National Registry of Chronic Total Occlusion Intervention).
    Lee MH; Lee JM; Kang SH; Yoon CH; Jang Y; Yu CW; Park HS; Lee SH; Hur SH; Kim MH; Rha SW; Gwon HC; Chae IH; Kim HS
    Am J Cardiol; 2015 Jul; 116(2):195-203. PubMed ID: 26001819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sirolimus-eluting stent versus bare metal stent in diabetic patients: the final five-year follow-up of the DIABETES trial.
    Jiménez-Quevedo P; Hernando L; Gómez-Hospital JA; Iñiguez A; SanRoman A; Alfonso F; Hernández-Antolín R; Angiolillo DJ; Bañuelos C; Escaned J; Gonzalo N; Fernández C; Macaya C; Sabaté M;
    EuroIntervention; 2013 Jul; 9(3):328-35. PubMed ID: 23518240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.